mito-extra® - medac GmbH

Doherty AP, Trendell-Smith N, Stirling R, Rogers H, Bellringer J
Perivesical fat necrosis after adjuvant intravesical chemotherapy
BJU-International, 1999; 83: 420-423
Durek C, Sellmann K, Jocham D, Böhle A
Effekt der Kurzzeit-Exposition von Blasentumorenzellen mit Zytostatika
Urologe (A), 2002; 41, Suppl. 1: S. 21 (DGU-Abstract)
Eastham JA, Huffman JL,
Technique of Mitomycin instillation in the treatment of upper urinary tract urothelial
tumors
J-Urol 1993; 324 - 325
Eijstein A, Knonagel H, Hotz E,
Reduced bladder capacity in patients receiving intravesikal chemoprophylaxis
with Mitomycin.
Br J Urol 1990; 66: 386
Engelmann U, Knopf HJ, Graff J
Interferon-alpha 2b instillation prophylaxis in superficial bladder cancer - a prospective,
controlled three-armed trial
Anti-Cancer-Drugs 1992; 3: 33-37
Flüchter STH, Harzmann R, Hlobil H, Erdmann W, Bichler KH
Lokale Chemotherapie des Harnblasenkarzinoms mit Mitomycin
Urologe (A) Jahr 1982; 21: 24-28
Friedman D, Mooppan UMM, Rosen Y, Kim H
The effect of intravesical instillations of thiotepa, Mitomycin, and adriamycin on
normal urothelium: an experimental study in rats
J-Urol 1991; 145: 1060 - 1063
Gårdmark T, Malmström PU, Wiklund P, Jahnson S, Wijkström H,
Wahlquist R
Long term follow up of a randomized study of BCG versus Mitomycin-C in high
risk superficial bladder cancer
J-Urol, 2004; 171, 4, Suppl.: Abstr. 277
Gao X, Au JLS, Badalament-RA, Wientjes-MG
Bladder tissue uptake of Mitomycin during intravesical therapy is linear with drug
concentration in urine
Clin-Canc-Res 1998; 3: 139 - 143
Gustafson H, Wijkström H, Nyman C, et al.
Prophylactic instillation therapy of superficial bladder cancer
Scan-J-Urol-Nephro-Suppl 1991; 138: 187-191
Hamdy FC, Hastie KJ, Kerry R, Williams JL
Mitomycin-C in superficial bladder cancer. Is long-term maintenance therapy
worthwhile after initial treatment?
Br-J-Urol, 1993; 71: 183-186
Harrison GS, Green DF, Newling DW, Richards B, Robinson MR, Smith PH.
A phase II study of intravesical Mitomycin in the treatment of superficial bladder
cancer.
Br J Urol. 1983; 55(6):676-9.
Hautumm B, Birke F, Grauel H
Experimentelle Untersuchungen zur Bedeutung des Refluxes bei der
Rezidivchemoprophylaxe des Harnblasenkarzinoms
Therapiewoche 1982; 32: 515-519
Heney NM, Koontz WW, Barton B, Soloway M, Trump DL, Hazra T,
Weinstein RS.
Intravesical thiotepa versus Mitomycin in patients with Ta, T1 and TIS transitional
cell carcinoma of the bladder: a phase III prospective randomized study.
J Urol. 1988; 140(6):1390-3.
59